{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:40:36Z","timestamp":1789508436068,"version":"build-2803163510"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Data on advanced therapy (AT) in patients with HIV and inflammatory bowel disease (HIV-IBD) are limited. We evaluated the safety and outcomes of AT in this population using real-world data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study in the TriNetX database (2015\u20132020). Adult patients with HIV-IBD on anti-retroviral therapy were identified using ICD-10 codes. Propensity score matching (PSM) adjusted for baseline clinical and demographic differences. Intervention(s) or Exposure(s) AT exposure identified via prescription codes of biologics or small molecules. Primary outcomes were serious infections, opportunistic infections, and incident cancers; secondary outcomes included IBD-related surgery and all-cause mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 3422 patients with HIV-IBD, 173 (5.05%) received AT. The most commonly used agents were infliximab (41.6%), adalimumab (36.4%), and ustekinumab (11.6%). Mean follow-up was 4.86 years (9861 patient-years). In the unmatched \u00adcohort, rates of serious infections (34.1% vs 36.9%, OR 0.86, P = .14) and opportunistic infections (26.6% vs 26.9%, OR 0.99, P = .94) were similar between patients receiving AT and those not receiving AT. After PSM (163 matched pairs), no significant differences were observed in serious infections (34.3% vs 35.6%, OR 0.85, P = .26), opportunistic infections (24.5% vs 28.2%, OR 0.83, P = .45), malignancy rate, IBD-related surgery, or mortality. Kaplan\u2013Meier analyses showed no statistically significant differences in the cumulative incidence of infections or mortality between groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>In this large multicenter cohort, AT use in HIV-IBD was rare but not associated with higher risks of infection, cancer, surgery, or death. These findings support the safety of AT in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izag015","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T12:45:36Z","timestamp":1768481136000},"page":"1452-1459","source":"Crossref","is-referenced-by-count":2,"title":["Safety and outcomes of advanced IBD therapies in patients with HIV: a propensity-matched cohort analysis"],"prefix":"10.1093","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-3749-2317","authenticated-orcid":false,"given":"Avneet","family":"Kaur","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, State University of New York, Upstate Medical University , Syracuse, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avleen","family":"Kaur","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, State University of New York, Upstate Medical University , Syracuse, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2162-2840","authenticated-orcid":false,"given":"Idan","family":"Goren","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, State University of New York, Upstate Medical University , Syracuse, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"2026072823463922900_izag015-B1","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1093\/cid\/cir626","article-title":"Morbidity and aging in HIV-infected persons: the Swiss HIV Cohort Study","volume":"53","author":"Hasse","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2026072823463922900_izag015-B2","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ijid.2023.12.009","article-title":"Incidence of bacterial respiratory infection and pneumonia in people with HIV with and without airflow limitation","volume":"139","author":"Heidari","year":"2024","journal-title":"Int J Infect Dis"},{"key":"2026072823463922900_izag015-B3","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/ueg2.12731","article-title":"Evolution of eligibility criteria in inflammatory bowel disease clinical trials: a clinical trial databank analysis","volume":"13","author":"Outtier","year":"2025","journal-title":"United European Gastroenterol J"},{"key":"2026072823463922900_izag015-B4","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1089\/apc.2022.0197","article-title":"Biologic therapies in HIV\/AIDS patients with inflammatory diseases: a systematic review of the literature","volume":"37","author":"Bang","year":"2023","journal-title":"AIDS Patient Care STDs"},{"key":"2026072823463922900_izag015-B5","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1177\/0956462416675109","article-title":"Systematic review of the efficacy and safety of biological therapy for inflammatory conditions in HIV-infected individuals","volume":"28","author":"Fink","year":"2017","journal-title":"Int J STD AIDS"},{"key":"2026072823463922900_izag015-B6","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1111\/apt.14930","article-title":"Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry","volume":"48","author":"Chaparro","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2026072823463922900_izag015-B7","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.cgh.2020.12.023","article-title":"Impact of HIV infection on the course of inflammatory bowel disease and drug safety profile: a multicenter GETAID study","volume":"20","author":"Guillo","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026072823463922900_izag015-B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11894-023-00914-4","article-title":"Managing IBD patients with concomitant HIV infection\u2014a systematic review","volume":"26","author":"Sousa","year":"2024","journal-title":"Curr Gastroenterol Rep"},{"key":"2026072823463922900_izag015-B9","doi-asserted-by":"publisher","first-page":"4278","DOI":"10.1002\/lary.31458","article-title":"Modified frailty index associates with transoral robotic surgery complications and survival: a national database study","volume":"134","author":"Jain","year":"2024","journal-title":"Laryngoscope"},{"key":"2026072823463922900_izag015-B10","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1093\/ecco-jcc\/jjab052","article-title":"ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease","volume":"15","author":"Kucharzik","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2026072823463922900_izag015-B11","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1053\/j.gastro.2018.04.012","article-title":"Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases","volume":"155","author":"Kirchgesner","year":"2018","journal-title":"Gastroenterology"},{"key":"2026072823463922900_izag015-B12","doi-asserted-by":"publisher","first-page":"izaf218","DOI":"10.1093\/ibd\/izaf218","article-title":"Comparative risk of serious infections associated with treatment of inflammatory bowel disease","volume":"16","author":"Khan","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"2026072823463922900_izag015-B13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2147\/OARRR.S87312","article-title":"Rheumatoid arthritis in patients with HIV: management challenges","volume":"8","author":"Carroll","year":"2016","journal-title":"Open Access Rheumatol"},{"key":"2026072823463922900_izag015-B14","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.3390\/microorganisms10101891","article-title":"Impact and tolerance of immunosuppressive treatments in patients living with HIV with inflammatory or autoimmune diseases","volume":"10","author":"Guitton","year":"2022","journal-title":"Microorganisms"},{"key":"2026072823463922900_izag015-B15","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/j.cgh.2020.10.039","article-title":"Contemporary risk of surgery in patients with ulcerative colitis and Crohn\u2019s disease: a meta-analysis of population-based cohorts","volume":"19","author":"Tsai","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026072823463922900_izag015-B16","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.14309\/ajg.0000000000002395","article-title":"Preoperative risk factors for adverse events in adults undergoing bowel resection for inflammatory bowel disease","volume":"118","author":"Fernandez","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"2026072823463922900_izag015-B17","doi-asserted-by":"publisher","first-page":"e974","DOI":"10.1016\/j.cgh.2020.10.008","article-title":"Rates of intestinal resection and colectomy in inflammatory bowel disease patients after initiation of biologics","volume":"20","author":"Khoudari","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026072823463922900_izag015-B18","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1097\/QAD.0000000000000071","article-title":"Malignancies in HIV\/AIDS: from epidemiology to therapeutic challenges","volume":"28","author":"Rubinstein","year":"2014","journal-title":"AIDS"},{"key":"2026072823463922900_izag015-B19","doi-asserted-by":"publisher","first-page":"546","DOI":"10.3390\/cancers16030546","article-title":"Cancer and HIV: the molecular mechanisms of the deadly duo","volume":"16","author":"Omar","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2026072823463922900_izag015-B20","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S1470-2045(24)00189-X","article-title":"Cancer risk in people living with HIV and solid organ transplant recipients","volume":"25","author":"Jin","year":"2024","journal-title":"Lancet Oncol"},{"key":"2026072823463922900_izag015-B21","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1038\/sj.ki.5000339","article-title":"A cross-sectional study of HIV-seropositive patients with varying degrees of proteinuria in South Africa","volume":"69","author":"Han","year":"2006","journal-title":"Kidney Int"},{"key":"2026072823463922900_izag015-B22","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1097\/QAI.0000000000001433","article-title":"Risk of colorectal cancer and associated mortality in HIV","volume":"75","author":"O\u2019Neill","year":"2017","journal-title":"JAIDS"},{"key":"2026072823463922900_izag015-B23","doi-asserted-by":"publisher","first-page":"e002282","DOI":"10.1136\/rmdopen-2022-002282","article-title":"Biological treatment usage in patients with HIV and rheumatic disease","volume":"8","author":"Naovarat","year":"2022","journal-title":"RMD Open"},{"key":"2026072823463922900_izag015-B24","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s00403-024-03395-1","article-title":"Systematic review of biologic use for psoriasis in HIV-positive individuals","volume":"317","author":"Shimon","year":"2024","journal-title":"Arch Dermatol Res"},{"key":"2026072823463922900_izag015-B25","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19020","article-title":"The impact of psoriasis biologic therapy on HIV viral load and CD4+ cell counts","author":"Xu","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026072823463922900_izag015-B26","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/2475530320954279","article-title":"Biologic treatment of 4 HIV-positive patients","volume":"6","author":"Myers","year":"2021","journal-title":"J Psoriasis Psoriatic Arthritis"},{"key":"2026072823463922900_izag015-B27","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1053\/j.gastro.2020.02.032","article-title":"Pretreatment frailty and infection risk in IBD","volume":"158","author":"Kochar","year":"2020","journal-title":"Gastroenterology"},{"key":"2026072823463922900_izag015-B28","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cgh.2019.02.044","article-title":"Comparative risk of serious infections with biologic and\/or immunosuppressive therapy in IBD","volume":"18","author":"Singh","year":"2020","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/8\/1452\/66864130\/izag015.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/8\/1452\/66864130\/izag015.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T03:46:44Z","timestamp":1785296804000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/32\/8\/1452\/8475250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":28,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,2,12]]},"published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izag015","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,2,12]]}}}